Sentiment Trading

Autolus Therapeutics PLC’s Q2 2025 earnings report reveals a mixed bag, with strong product revenue offset by significant operational losses, leaving investors uncertain about the company’s long-term viability.

Autolus Therapeutics PLC has reported promising long-term results from its FELIX study, demonstrating the potential of its Obe-Cel cell therapy to induce durable remission in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Autolus Therapeutics PLC reported a promising start to 2025, with its flagship product AUCATZYL generating $9.0 million in net product revenue and receiving conditional marketing authorization in the UK.